Use of second-generation antiandrogens: cognitive and functional side effects

A review and analysis examined the use of second-generation antiandrogens (AAs) for treating prostate cancer and their potential cognitive and functional side effects. These AAs, including abiraterone, apalutamide, darolutamide, and enzalutamide, are becoming more frequently used in treatment. The researchers examined data from 12 studies involving 13,524 participants and found that those treated with second-generation AAs had a higher risk of experiencing cognitive issues, fatigue, and falls compared to control groups. Even when used with traditional hormone therapy, the risk remained. Older age was linked to a higher risk of fatigue with these AAs. More research is needed to better understand and manage these potential side effects in prostate cancer treatment.